Clinical trials: Age 65 and Older
Influenza
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly. Primary objective: To measure the efficacy of the vaccine, defined as the prevention of…
- Trial name
- NCT00976027
- Testing
- Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine
- Where
- 98 sites in United States, Puerto Rico
- Volunteers
- 9,172 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza, Human
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.
- Trial name
- NCT04789577
- Testing
- FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3
- Where
- 8 sites in United States
- Volunteers
- 833 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Newly Diagnosed Multiple Myeloma
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.
- Trial name
- NCT00405756
- Testing
- Lenalidomide: Double-blind Induction, Melphalan, Prednisone
- Where
- 98 sites in Australia, Austria and 20 more
- Volunteers
- 459 people
- Sponsor
- Celgene Corporation
Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine
A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine compared to a single dose of 23-valent pneumococcal polysaccharide vaccine in…
- Trial name
- NCT01646398
- Testing
- 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine
- Where
- 8 sites in Japan
- Volunteers
- 764 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Viruses, Respiratory Tract Diseases
A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older
The purpose of this study is to demonstrate the efficacy of active study vaccine in the prevention of reverse transcriptase polymerase chain reaction (RT-PCR) confirmed respiratory syncytial virus (RSV)-mediated lower respiratory…
- Trial name
- CYPRESS (NCT03982199)
- Testing
- RSV Vaccine
- Where
- 40 sites in United States
- Volunteers
- 5,815 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Influenza
Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older
This randomized, partially-blinded, active comparator-controlled was conducted at multiple sites globally. The composition of QVLP used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins…
- Trial name
- NCT04622592
- Testing
- Instramuscular vaccine
- Where
- 14 sites in United States
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Medicago
Pneumococcal Disease
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination
This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination
- Trial name
- NCT03835975
- Testing
- 13vPnC, PPSV23, 20vPnC
- Where
- 42 sites in United States, Sweden
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- Pfizer
Multiple Myeloma
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.
- Trial name
- NCT01453088
- Testing
- Melphalan, Bortezomib
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Hackensack Meridian Health
Flu Vaccine
Senescent Immunity in Elders and Vaccine Responses (SILVER)
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
- Trial name
- NCT04077424
- Testing
- Fluzone-High Dose Quadrivalent, Fluad, Flublock
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment.
- Trial name
- NCT03737981
- Testing
- Ibrutinib, Obinutuzumab, Observation Activity
- Where
- 857 sites in United States
- Volunteers
- 465 people
- Sponsor
- National Cancer Institute (NCI)
Anemia
Trial To Evaluate the Efficacy of Oral Salsalate in the Treatment of Older Adults With Unexplained Anemia
The purpose of this study is to determine whether treatment of unexplained anemia in older adults and elevated inflammatory markers with oral salsalate can improve hemoglobin levels and improve physical activity and quality of…
- Trial name
- NCT01506726
- Testing
- Salsalate
- Where
- 12 sites in United States
- Volunteers
- 11 people
- Sponsor
- Harvey Jay Cohen
Hypertension
Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension
To characterize the safety, tolerability, and efficacy profile of amlodipine/valsartan 5/80 mg as compared to amlodipine/valsartan 5/40 mg (with optional titration to 5/80 mg) and amlodipine 5 mg monotherapy in elderly patients…
- Trial name
- NCT00699192
- Testing
- Amlodipine 5 mg, Valsartan 80 mg, Valsartan 40 mg
- Where
- 18 sites in Czechia, Finland and 8 more
- Volunteers
- 965 people
- Sponsor
- Novartis Pharmaceuticals
Tetanus, Acellular Pertussis
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
This phase IIIb, observer-blind study will evaluate the immunogenicity and safety of GSK Biologicals' Boostrix® vaccine in adults (extending indication) aged 65 years or older.
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines
- Trial name
- NCT00835237
- Testing
- Boostrix®, Decavac™
- Where
- 24 sites in United States
- Volunteers
- 1,332 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents
The primary purpose of this study is to assess humoral immune responses of 3 dose levels of Ad26.COV2.S administered intramuscularly (IM) as a 2-dose schedule (56 days apart); Ad26.COV2.S administered IM as a single vaccination…
- Trial name
- NCT04535453
- Testing
- Ad26.COV2.S
- Where
- 13 sites in Germany, Netherlands and 2 more
- Volunteers
- 635 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Influenza, Human
A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter [mL]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a…
- Trial name
- NCT05648357
- Testing
- Fluarix Tetra Vaccine
- Where
- 6 sites in India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline